Results 21 to 30 of about 27,935 (169)

Global Pandemic Conditions and List of Possible Medications and Vaccines for the Treatment of COVID-19: A Review

Borneo Journal of Pharmacy, 2020
At the end of December 2019, a novel coronavirus was identified which caused severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with a disease known as coronavirus disease 2019 (COVID-19).
Mohammad Mukim, Atul Kabra, Siwani Devi, Mohit Chaturvedi, Rakesh Patel   +4 more
doaj   +1 more source

COVID‐19: A review of therapeutics under investigation

Journal of the American College of Emergency Physicians Open, 2020
The COVID‐19 outbreak has disrupted global health care networks and caused thousands of deaths and an international economic downturn. Multiple drugs are being used on patients with COVID‐19 based on theoretical and in vitro therapeutic targets.
James C. Crosby, Matthew A. Heimann, Samuel L. Burleson, Brendan C. Anzalone, Jonathan F. Swanson, Douglas W. Wallace, Christopher J. Greene   +6 more
doaj   +1 more source

Amino Acid Prodrugs: An Approach to Improve the Absorption of HIV-1 Protease Inhibitor, Lopinavir

Pharmaceuticals, 2014
Poor systemic concentrations of lopinavir (LPV) following oral administration occur due to high cellular efflux by P-glycoprotein (P-gp) and multidrug resistance-associated proteins (MRPs) and extensive metabolism by CYP3A4 enzymes.
Mitesh Patel, Nanda Mandava, Mitan Gokulgandhi, Dhananjay Pal, Ashim K. Mitra   +4 more
doaj   +1 more source

Simultaneous determination of plasma lopinavir and ritonavir by chemometrics-assisted spectrophotometry and comparison with HPLC method [PDF]

Maejo International Journal of Science and Technology, 2013
Chemometrics-assisted spectrophotometry for the determination of two protease inhibitors, lopinavir and ritonavir, in plasma was evaluated. A set of calibration mixtures (calibration set) was designed according to central composite design. The UV spectra
Chutima Matayatsuk Phechkrajang
doaj  

Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial

International Journal of Cardiology: Heart & Vasculature, 2021
Introduction: Efficacious therapies are urgently required to tackle the coronavirus disease 2019 (COVID-19). This trial aims to evaluate the effects of atorvastatin in comparison with standard care for adults hospitalized with COVID-19.
Lotfollah Davoodi, Hamed Jafarpour, Ziaeddin Oladi, Zakaria Zakariaei, Mohammad Tabarestani, Bahareh Moayed Ahmadi, Alireza Razavi, Amirhossein Hessami   +7 more
doaj   +1 more source

The Rationale for Potential Pharmacotherapy of COVID-19

Pharmaceuticals, 2020
On 11 March 2020, the coronavirus disease (COVID-19) was defined by the World Health Organization as a pandemic. Severe acute respiratory syndrome-2 (SARS-CoV-2) is the newly evolving human coronavirus infection that causes COVID-19, and it first ...
Maha Saber-Ayad, Mohamed A. Saleh, Eman Abu-Gharbieh   +2 more
doaj   +1 more source

Severe COVID-19 infection in a kidney transplant recipient treated with lopinavir/ritonavir, hydroxychloroquine and dexamethasone

Journal of Infection in Developing Countries, 2021
Severe COVID-19 infection management for a recipient of kidney transplant has debatable prognosis and treatment. We described the case of a COVID-19 infected 70 year old female, previously had renal transplantation in 2017.
Satriyo Dwi Suryantoro, Mochammad Thaha, Pranawa, Djoko Santoso, Nunuk Mardiana, Widodo, Aditiawardana, Artaria Tjempakasari, Ardityo Rahmat Ardhany, Dana Pramudya, Decsa Medika Hertanto, Evy Febriane, Meryana, Maria Angela, Ari Christy Muliono, Handoko Tanuwidjaja, Philia Setiawan, David Sugiarto   +17 more
doaj   +1 more source

Deep Contrastive Learning for High‐Throughput Prediction of Drug Resistance Mutations from Sequences

Advanced Science, EarlyView.
This study presents DeepMutDTA, a deep learning framework aimed at predicting mutation‐induced changes in protein‐drug interactions and prioritizing variants potentially linked to drug resistance. Trained on large‐scale data, it incorporates SimSiam‐MuTF, a label‐aware contrastive fine‐tuning strategy that encourages separation between WT and MT ...
Xiaowen Hu, Pan Zhang, Shangqian Wu, Hao Sun, Minwei Li, Sophia Tsoka, Zizhang Sheng, Lei Deng   +7 more
wiley   +1 more source

Clinical and Immunological Outcomes after Initiation of Second Line Antiretroviral Therapy in People Living with HIV [PDF]

Journal of Clinical and Diagnostic Research, 2019
Introduction: Resistance to first-line Antiretroviral Therapy (ART) has been a major concern in People Living with HIV (PLHIV), which necessitates a switch to second-line therapy.
BASAVAPRABHU ACHAPPA, DEEPAK MADI, MOHAMMAD YOUSUFF, SATISH RAO, JOHN RAMAPURAM   +4 more
doaj   +1 more source

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Balcinrenone (previously AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist (MRA) with a differential mechanism of action relative to approved MRAs. The aim of this trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone in participants with mild and moderate hepatic impairment ...
Anna L. Eriksson, Deeyen Karsanji, Bonifride Tuyishimire, Joanna Parkinson, Maria Heijer, Tadeusz Pawlik, Judith Hartleib‐Geschwindner, Maria Leonsson‐Zachrisson, Hans Ericsson   +8 more
wiley   +1 more source